Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 1997

View Archived Issues

SciClone awarded grant for clinical development of cystic fibrosis therapy

Quidel and Glaxo Wellcome sign agreement for diagnostic tests

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Nastech files IND for new formulation of buprenorphine

Spotlight on angiotensin II blocker/ACE inhibitor combination therapy

Patent issued for Fluorovent technology

FDA approval granted for Carbatrol

Hoechst discloses antiischemic agents

Novel neural antiapoptotic polypeptide discovered by Novartis

Aviron updates vaccine clinical program

BMS and ICAgen establish ion channel collaboration

Vanguard licenses VML-252 to Sankyo

Phase II results for ganaxolone in epilepsy and migraine anticipated by year-end

PathoGenesis receives grant for new antibiotic for CF infections

Scios/Wyeth-Ayerst commence large pivotal trials of bFGF for stroke

New immunotherapy for metastatic tumors reported

Selective iNOS inhibitor inhibits tumor growth in mice

Collagen to spin off two companies

Progress made on MMAC-1 research; Schering-Plough acquires rights to therapies

Renal effects of NO donor FK-409 in dogs

Demeter BioTechnologies awarded grant for cancer therapeutics program

VA-045 effective against TBI-induced retrograde and anterograde amnesia

ImmuCell receives grant to develop TravelGAM

DUROS leuprolide enters phase III for prostate cancer

Cubist and Merck expand antibiotic collaboration

Important NRC discovery related to stroke and epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...